Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 53.76
NAS:DCPH's Cash-to-Debt is ranked higher than
50% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. NAS:DCPH: 53.76 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:DCPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.81  Med: 44.11 Max: 59.68
Current: 53.76
13.81
59.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA % -67.37
NAS:DCPH's ROA % is ranked lower than
72% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. NAS:DCPH: -67.37 )
Ranked among companies with meaningful ROA % only.
NAS:DCPH' s ROA % Range Over the Past 10 Years
Min: -73.97  Med: -67.24 Max: -60.51
Current: -67.37
-73.97
-60.51
ROC (Joel Greenblatt) % -8450.98
NAS:DCPH's ROC (Joel Greenblatt) % is ranked lower than
85% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. NAS:DCPH: -8450.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:DCPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8450.98  Med: -5142.07 Max: -4549.61
Current: -8450.98
-8450.98
-4549.61
GuruFocus has detected 1 Warning Sign with Deciphera Pharmaceuticals Inc NAS:DCPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:DCPH's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

DCPH Guru Trades in

DCPH Guru Trades in

Q3 2017

DCPH Guru Trades in Q3 2017

Paul Tudor Jones 52,630 sh (New)
Andreas Halvorsen 2,491,542 sh (New)
» More
Q4 2017

DCPH Guru Trades in Q4 2017

Paul Tudor Jones Sold Out
Andreas Halvorsen 2,394,625 sh (-3.89%)
» More
» Details

Insider Trades

Latest Guru Trades with DCPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Deciphera Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:DOVA, HKSE:00775, NAS:RETA, NAS:ABEO, ROCO:4162, NAS:ACIU, NAS:ANIP, TSX:PLI, OSTO:RECI B, NAS:ACRS, NAS:LJPC, ASX:SRX, HKSE:06826, NYSE:MYOV, NAS:INSY, XKRX:096530, NAS:AKBA, TSE:2160, NAS:ALDR, SZSE:300181 » details
Traded in other countries:D05.Germany,
Headquarter Location:USA
Deciphera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients.

Deciphera Pharmaceuticals Inc is a biotechnology company, develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations are functioned through the region of US.

Top Ranked Articles about Deciphera Pharmaceuticals Inc

Consolidated Research: 2018 Summary Expectations for ShotSpotter, Deciphera Pharmaceuticals, Ryman Hospitality Properties, Community Bank System, InfraREIT, and USANA Health Sciences — Fundamental Analysis, Key Performance Indications
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) to Ring The Nasdaq Stock Market Opening Bell
Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Andreas Halvorsen Dives into Deciphera Pharma Company launches initial public offering and reports recent study results
Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks. Read more...

Ratios

vs
industry
vs
history
Current Ratio 8.21
DCPH's Current Ratio is ranked higher than
74% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. DCPH: 8.21 )
Ranked among companies with meaningful Current Ratio only.
DCPH' s Current Ratio Range Over the Past 10 Years
Min: 8.21  Med: 10.09 Max: 12.78
Current: 8.21
8.21
12.78
Quick Ratio 8.21
DCPH's Quick Ratio is ranked higher than
75% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. DCPH: 8.21 )
Ranked among companies with meaningful Quick Ratio only.
DCPH' s Quick Ratio Range Over the Past 10 Years
Min: 8.21  Med: 10.09 Max: 12.78
Current: 8.21
8.21
12.78

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -3.21
DCPH's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. DCPH: -3.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DCPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.23  Med: 0 Max: 0
Current: -3.21
-6.23
0

More Statistics

EPS (TTM) $ -6.73
Short Percentage of Float4.15%
52-Week Range $15.15 - 29.98
Shares Outstanding (Mil)32.59

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}